CLAGE-VEN Sequential With Reduced Dose MBF for Refractory AML
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
We developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide
(CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu
to treat patients with refractory AML. In this study, we further evaluate the protocol with
modifications: 1) reduced dose of CLAGE; 2) RIC conditioning regimen as Flu-Bu-Mel; 3)
Venetoclax was added to the chemotherapy and conditioning regimen.